Effect of Tanshinone IIA for Myocardial Ischemia/reperfusion Injury in Animal Model: Preclinical Evidence and Possible Mechanisms

Overview

Journal Front Pharmacol

Date 2023 Jun 1

PMID 37261285

Authors

Peng-Chong Zhu

Jiayi Shen

Ren-Yi Qian

Jian Xu

Chong Liu

Wu-Ming Hu

Ying Zhang

Ling-Chun Lv

Affiliations

Soon will be listed here.

Abstract

Tanshinone IIA (Tan IIA), the major active lipophilic ingredient of , exerts various therapeutic effects on the cardiovascular system. We aimed to identify the preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent in the treatment of myocardial ischemia/reperfusion injury. The study quality scores of twenty-eight eligible studies and data analyses were separately assessed using the CAMARADES 10-item checklist and Rev-Man 5.3 software. The study quality score ranged from 3/10 to 7/10 points. The present study provided preliminary preclinical evidence that Tan IIA could significantly decrease the myocardial infarct size, cardiac enzyme activity and troponin levels compared with those in the control group (). Tan IIA alleviated myocardial I/R injury via antioxidant, anti-inflammatory, anti-apoptosis mechanisms and improved circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent for the treatment of myocardial ischemia/reperfusion injury and should be further investigated in clinical trials.

Citing Articles

Chinese and western medicine treatment of myocardial fibrosis drugs.

Zhu Y, Zhang F, Li Z, Zhou Y, Shu Y, Ruan J Front Cardiovasc Med. 2025; 11:1477601.

PMID: 39882321 PMC: 11774883. DOI: 10.3389/fcvm.2024.1477601.

Tanshinone IIA Protects Ischemia/Reperfusion-Induced Cardiomyocyte Injury by Inhibiting the / Axis.

Wang Y, Sun W, Shen L, Yu P, Shen Q, Zhou Y Cardiol Res Pract. 2024; 2024:2581638.

PMID: 39568660 PMC: 11578662. DOI: 10.1155/2024/2581638.

Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.

Dai J, Qiu L, Lu Y, Li M Front Endocrinol (Lausanne). 2024; 15:1366285.

PMID: 39403576 PMC: 11471557. DOI: 10.3389/fendo.2024.1366285.

Inflammation and coronary microvascular disease: relationship, mechanism and treatment.

Guo Z, Yang Z, Song Z, Li Z, Xiao Y, Zhang Y Front Cardiovasc Med. 2024; 11:1280734.

PMID: 38836066 PMC: 11148780. DOI: 10.3389/fcvm.2024.1280734.

Expanding the therapeutic potential of : a review of its pharmacological applications in musculoskeletal diseases.

Ye Z, Liu Y, Song J, Gao Y, Fang H, Hu Z Front Pharmacol. 2023; 14:1276038.

PMID: 38116081 PMC: 10728493. DOI: 10.3389/fphar.2023.1276038.

References

Lecour S, Botker H, Condorelli G, Davidson S, Garcia-Dorado D, Engel F . ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014; 104(3):399-411. PMC: 4242141. DOI: 10.1093/cvr/cvu225. View

Macleod M, OCollins T, Howells D, Donnan G . Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004; 35(5):1203-8. DOI: 10.1161/01.STR.0000125719.25853.20. View

Thind G, Agrawal P, Hirsh B, Saravolatz L, Chen-Scarabelli C, Narula J . Mechanisms of myocardial ischemia-reperfusion injury and the cytoprotective role of minocycline: scope and limitations. Future Cardiol. 2015; 11(1):61-76. DOI: 10.2217/fca.14.76. View

Landis S, Amara S, Asadullah K, Austin C, Blumenstein R, Bradley E . A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012; 490(7419):187-91. PMC: 3511845. DOI: 10.1038/nature11556. View

Ferdinandy P, Hausenloy D, Heusch G, Baxter G, Schulz R . Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014; 66(4):1142-74. DOI: 10.1124/pr.113.008300. View

Garcia-Bonilla L, Campos M, Giralt D, Salat D, Chacon P, Hernandez-Guillamon M . Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J Neurochem. 2012; 122(2):233-43. DOI: 10.1111/j.1471-4159.2012.07773.x. View

Barrett-Connor E . Gender differences and disparities in all-cause and coronary heart disease mortality: epidemiological aspects. Best Pract Res Clin Endocrinol Metab. 2013; 27(4):481-500. PMC: 3781943. DOI: 10.1016/j.beem.2013.05.013. View

Tsao C, Aday A, Almarzooq Z, Alonso A, Beaton A, Bittencourt M . Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022; 145(8):e153-e639. DOI: 10.1161/CIR.0000000000001052. View

Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L . Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab. 2010; 12(4):316-22. DOI: 10.1111/j.1463-1326.2009.01166.x. View

10.

Yellon D, Hausenloy D . Myocardial reperfusion injury. N Engl J Med. 2007; 357(11):1121-35. DOI: 10.1056/NEJMra071667. View

11.

Shao H, Li M, Chen F, Chen L, Jiang Z, Zhao L . The Efficacy of Danshen Injection as Adjunctive Therapy in Treating Angina Pectoris: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2017; 27(4):433-442. DOI: 10.1016/j.hlc.2017.10.016. View

12.

Briel M, Muller K, Meerpohl J, von Elm E, Lang B, Motschall E . Publication bias in animal research: a systematic review protocol. Syst Rev. 2013; 2:23. PMC: 3651300. DOI: 10.1186/2046-4053-2-23. View

13.

Hausenloy D, Yellon D . Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther. 2007; 116(2):173-91. DOI: 10.1016/j.pharmthera.2007.06.005. View

14.

Ansari M, Khan F, Safdari H, Almatroudi A, Alzohairy M, Safdari M . Prospective therapeutic potential of Tanshinone IIA: An updated overview. Pharmacol Res. 2020; 164:105364. DOI: 10.1016/j.phrs.2020.105364. View

15.

Menazza S, Sun J, Appachi S, Chambliss K, Kim S, Aponte A . Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice. J Mol Cell Cardiol. 2017; 107:41-51. PMC: 5514412. DOI: 10.1016/j.yjmcc.2017.04.004. View

16.

Bulluck H, Yellon D, Hausenloy D . Reducing myocardial infarct size: challenges and future opportunities. Heart. 2015; 102(5):341-8. PMC: 4789695. DOI: 10.1136/heartjnl-2015-307855. View

17.

Bae S, Zhang L . Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: focus on Akt and protein kinase C signaling. J Pharmacol Exp Ther. 2005; 315(3):1125-35. DOI: 10.1124/jpet.105.090803. View

18.

Luo H, Vong C, Chen H, Gao Y, Lyu P, Qiu L . Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019; 14:48. PMC: 6836491. DOI: 10.1186/s13020-019-0270-9. View

19.

Blankstein R, Ahmed W, Bamberg F, Rogers I, Schlett C, Nasir K . Comparison of exercise treadmill testing with cardiac computed tomography angiography among patients presenting to the emergency room with chest pain: the Rule Out Myocardial Infarction Using Computer-Assisted Tomography (ROMICAT) study. Circ Cardiovasc Imaging. 2012; 5(2):233-42. DOI: 10.1161/CIRCIMAGING.111.969568. View

20.

Roberts I, Kwan I, Evans P, Haig S . Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ. 2002; 324(7335):474-6. PMC: 1122396. DOI: 10.1136/bmj.324.7335.474. View